Leap Therapeutics Inc (OQ:LPTX)

Apr 11, 2024 08:30 am ET
Leap Therapeutics Announces $40 Million Private Placement
Net proceeds, along with existing cash, cash equivalents, and marketable securities are expected to extend cash runway into Q2 2026 and enable expansion of DKN-01 DeFianCe clinical trial and development program
Jan 16, 2024 04:05 pm ET
Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium
30% ORR and 93% DCR across heterogenous second-line CRC patientstreated with DKN-01 plus bevacizumab and chemotherapy
Jan 03, 2024 06:00 am ET
Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 3, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
Jan 02, 2024 06:00 am ET
Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients
CAMBRIDGE, Mass. , Jan. 2, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that enrollment has been completed in the randomized controlled Part C of the DisTinGuish study evaluating DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody, in combination with tislelizumab, BeiGene's anti-PD-1 antibody, and chemotherapy in patients with advanced gastroesophageal junction and gastric cancer.
Dec 11, 2023 03:05 pm ET
Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium
CAMBRIDGE, Mass., Dec. 11, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the Company will be presenting new data in second-line patients with advanced colorectal cancer from the DeFianCe study, a Phase 2 study evaluating DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody, in combination with standard of care bevacizumab and chemotherapy at the upcoming 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium taking place in San Francisco, CA and
Nov 21, 2023 06:00 am ET
Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference
CAMBRIDGE, Mass., Nov. 21, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York, NY.
Nov 13, 2023 06:00 am ET
Leap Therapeutics Reports Third Quarter 2023 Financial Results
CAMBRIDGE, Mass., Nov. 13, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2023.
Jul 12, 2023 07:00 am ET
Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients
CAMBRIDGE, Mass., July 12, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that, based on the early efficacy and momentum seen in the enrollment of 33 patients with colorectal cancer (CRC) in its DeFianCe study, it has initiated the 130 patient randomized controlled Part B of the Phase 2 study. The study evaluates Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with standard of care bevacizumab and chemotherapy as a second-line treatment for patients with advanc
Jun 20, 2023 12:30 pm ET
Leap Therapeutics Announces Reverse Stock Split
CAMBRIDGE, Mass., June 20, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it will effect a 10-for-1 reverse stock split of its issued and outstanding common stock, effective at 5PM ET on June 20, 2023. Leap expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on June 21, 2023.
May 25, 2023 05:10 pm ET
Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting
19.5 months median OS in the overall first-line patient population, exceeding current benchmarksLong-term follow-up identifies additional patient with partial response, resulting in 73% ORR in overall mITT population, including 86% ORR in PD-L1-low patientsCAMBRIDGE, Mass., May 25, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting new long-term follow-up data in first-line patients with advanced gastric or gastroesophageal junction adenocarcinoma
May 18, 2023 11:40 am ET
Thinking about buying stock in X4 Pharmaceuticals, Snowflake, Leap Therapeutics, Arbor Realty, or Microvision?
NEW YORK, May 18, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for XFOR, SNOW, LPTX, ABR, and MVIS.
May 15, 2023 07:00 am ET
Leap Therapeutics Reports First Quarter 2023 Financial Results
CAMBRIDGE, Mass., May 15, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for first quarter ended March 31, 2023.
Apr 26, 2023 04:05 pm ET
Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting
CAMBRIDGE, Mass., April 26, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused  on developing targeted and immuno-oncology therapeutics, today announced that the Company will be presenting new long-term follow-up data in first-line patients with advanced gastroesophageal adenocarcinoma (GEA) from Part A of the DisTinGuish study, a Phase 2 clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab and chemotherapy, at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking pl
Apr 12, 2023 07:00 am ET
Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients
CAMBRIDGE, Mass., April 12, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused  on developing targeted and immuno-oncology therapeutics, today announced that enrollment has been completed in Part A of the Phase 2 DeFianCe study evaluating DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody, in combination with standard of care bevacizumab and chemotherapy as a second-line treatment for patients with advanced colorectal cancer (CRC).
Mar 24, 2023 07:00 am ET
Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
CAMBRIDGE, Mass., March 24, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2022.
Mar 16, 2023 04:05 pm ET
Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01
DisTinGuish Trial of DKN-01 plus tislelizumab and chemotherapy to continue as a clinical collaboration
Feb 08, 2023 12:27 pm ET
Moore Kuehn Encourages ALBO, LPTX, ALR, and CEMI Investors to Contact Law Firm
Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek...
Feb 07, 2023 12:17 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CNCE, AQUA, LPTX, ALR
NEW YORK, Feb. 7, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Feb 05, 2023 10:59 pm ET
Moore Kuehn Encourages ALR, CEMI, LPTX, and ATCX Investors to Contact Law Firm
NEW YORK, Feb. 5, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.  Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies:
Feb 05, 2023 10:13 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AQUA, LPTX, ALR
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Evoqua Water Technologies Corp. (NYSE:...
Feb 04, 2023 08:01 pm ET
Lifshitz Law PLLC Announces Investigations of ATCX, CEMI, LPTX, and AQUA
Atlas Technical Consultants, Inc. (NASDAQ: ATCX) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of ATCX to GI Partners for $12.25 per share in cash. If you are an ATCX...
Jan 31, 2023 09:45 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALBO, CNCE, AQUA, LPTX
NEW YORK, Jan. 31, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jan 25, 2023 09:28 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LPTX, DCT, AQUA, ISO
NEW YORK, Jan. 25, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jan 24, 2023 03:16 pm ET
LPTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Leap Therapeutics, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Leap Therapeutics, Inc. (NASDAQ: LPTX) and Flame Biosciences, Inc. is fair to Leap shareholders. Under the terms of the merger agreement, Leap will issue approximately 19,794,373 shares of its common stock and approximately 136,833 shares of a newly designated Series X non-voting convertible preferred stock to Flame stockholders.
Jan 18, 2023 04:55 pm ET
STOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Leap Therapeutics, Inc. - LPTX
NEW YORK, Jan. 18, 2023 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Leap Therapeutics, Inc. (NASDAQ: LPTX), relating to its proposed purchase of Flame Biosciences, Inc. Under the terms of the agreement, LPTX will issue shares of common stock and Series X non-voting convertible preferred stock to Flame sha
Jan 18, 2023 04:23 pm ET
SHAREHOLDER ALERT: Weiss Law Investigates Leap Therapeutics, Inc.
NEW YORK, Jan. 18, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Leap Therapeutics, Inc. ("Leap" or the "Company") (NASDAQ: LPTX), in connection with the proposed purchase of Flame Biosciences, Inc. ("Flame"). Under the terms of the merger agreement, the Company will issue approximately 19,794,373 shares of its common stock and approximately 136,833 shares of a newly designated Series X non-voting convertible preferred stock to Flame shareholders. Upon approval of the transaction, each share of the
Jan 17, 2023 07:00 am ET
Leap Therapeutics Acquires Flame Biosciences
Adds FL-301, clinical stage anti-Claudin18.2 antibody, and two preclinical antibody programs to Leap's pipeline
Jan 11, 2023 06:00 am ET
Leap Therapeutics to Present at B. Riley Securities' 3rd Annual Oncology Conference
CAMBRIDGE, Mass., Jan. 11, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, Cynthia Sirard, MD, Chief Medical Officer, and Jason Baum, PhD., Vice President and Head of Translational Medicine will present a corporate overview at B. Riley Securities' 3rd Annual Oncology Conference. The conference will be held in a virtual meeting format.
Nov 21, 2022 06:00 am ET
Leap Therapeutics to Participate at the Piper Sandler 34th Annual Healthcare Conference
CAMBRIDGE, Mass., Nov. 21, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference, being held in New York on November 29-December 1, 2022.
Nov 14, 2022 06:00 am ET
Leap Therapeutics Reports Third Quarter 2022 Financial Results
CAMBRIDGE, Mass., Nov. 14, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2022.
Nov 07, 2022 07:05 am ET
Oct 17, 2022 07:00 am ET
Leap Therapeutics Announces First Patient Enrolled in DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients
CAMBRIDGE, Mass., Oct. 17, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused  on developing targeted and immuno-oncology therapeutics, today announced that the first patient has been enrolled in the Phase 2 DeFianCe study evaluating DKN-01, Leap's anti-Dickkopf-1 antibody (DKK1), in combination with standard of care bevacizumab and chemotherapy as a second-line treatment for patients with advanced colorectal cancer (CRC).
Oct 12, 2022 07:00 am ET
Leap Therapeutics Announces First Patient Enrolled in Part C of Phase 2 DisTinGuish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer
CAMBRIDGE, Mass., Oct. 12, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the first patient has been enrolled in the randomized controlled Part C of the ongoing DisTinGuish study to evaluate DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody, in combination with tislelizumab, BeiGene's anti-PD-1 antibody, and chemotherapy compared to a tislelizumab and chemotherapy control arm, in patients with gastric or gastroesophageal junction cancer (G/GEJ).
Oct 05, 2022 08:05 am ET
Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting
CAMBRIDGE, Mass., Oct. 5, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting updated data from Part B of the DisTinGuish Study evaluating DKN-01 in combination with tislelizumab, BeiGene's anti-PD-1 antibody, in second-line gastroesophageal junction/gastric (GEJ/G) cancer patients whose tumors express high levels of DKK1 (DKK1-high) at the Society of Immunotherapy for Cancer (SITC) 37th Annual Meeting being held in Boston, MA on November 8-12, 2022
Sep 27, 2022 08:15 am ET
Arthur Tzianabos, Ph.D., June Lee, MD FACCP, and Joseph Loscalzo, MD, Ph.D. Join 5AM Ventures
5AM Ventures, a bicoastal venture capital firm, continues to attract preeminent talent as it celebrates 20 years of investing in early-stage life science companies. The firm is currently deploying capital in breakthrough science opportunities...
Sep 09, 2022 09:38 am ET
Thinking about buying stock in Hut 8 Mining, Leap Therapeutics, Pinterest, CleanSpark, or AMC Entertainment?
NEW YORK, Sept. 9, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HUT, LPTX, PINS, CLSK, and AMC.
Sep 07, 2022 07:00 am ET
Leap Therapeutics to Participate at the Baird 2022 Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 7, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will participate in a fireside chat at the Baird 2022 Global Healthcare Conference, being held in New York on September 13-14, 2022.
Sep 06, 2022 07:00 am ET
Leap Therapeutics Announces Appointment of Richard L. Schilsky, MD to its Board of Directors
CAMBRIDGE, Mass., Sept. 6, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused  on developing targeted and immuno-oncology therapeutics, today announced the appointment of Richard L. Schilsky, MD, FASCO, FACP, FSCT to its Board of Directors, effective September 1, 2022. Dr. Schilsky brings over 40 years of experience in medicine and clinical research, specializing in new drug development and clinical trials for a wide range of cancers.
Sep 04, 2022 06:05 pm ET
Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq® at the ESMO Congress
Median Progression-Free Survival of 11.3 months in first-line gastric cancer patients treated with DKN-01 plus tislelizumab and CAPOX, exceeding benchmarks in the overall population and in DKK1 and PD-L1 subgroups
Aug 12, 2022 07:00 am ET
Leap Therapeutics Reports Second Quarter 2022 Financial Results
CAMBRIDGE, Mass., Aug. 12, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter ended June 30, 2022.
Aug 12, 2022 07:00 am ET
Jul 12, 2022 07:00 am ET
Leap Therapeutics Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer
Randomized Controlled First-Line Gastric Cancer Trial of DKN-01 plus tislelizumab and chemotherapy in collaboration with BeiGene
Jun 27, 2022 07:00 am ET
Leap Therapeutics to Host Virtual R&D Day on July 12, 2022
CAMBRIDGE, Mass., June 27, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it will host a virtual R&D Day on July 12, 2022 at 12:00 pm ET. Leap's executive management team will be joined by distinguished key opinion leaders to share emerging data for the Company's lead clinical candidate, DKN-01, a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, and provide updates to its clinical development strategy.
May 26, 2022 05:00 pm ET
Leap Therapeutics to Present Initial Data from the Investigator-Sponsored Study of DKN-01 Plus Docetaxel in Patients with Prostate Cancer at the 2022 ASCO Annual Meeting
CAMBRIDGE, Mass., May 26, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that initial clinical data from the investigator-sponsored Phase 1b/2a dose escalation and dose expansion study testing Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, as monotherapy or in combination with docetaxel in metastatic castration-resistant prostate cancer (mCRPC) will be presented at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL on J
May 13, 2022 09:31 am ET
Thinking about buying stock in Eos Energy Enterprises, Payoneer Global, Leap Therapeutics, Moneylion, or Indie Semiconductor?
NEW YORK, May 13, 2022  /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EOSE, PAYO, LPTX, ML, and INDI.
May 13, 2022 07:00 am ET
Leap Therapeutics Reports First Quarter 2022 Financial Results
CAMBRIDGE, Mass., May 13, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2022.
Mar 11, 2022 06:00 am ET
Leap Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
CAMBRIDGE, Mass., March 11, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2021.
Mar 02, 2022 06:00 am ET
Leap Therapeutics to Present at Raymond James 43rd Annual Institutional Investors Conference
CAMBRIDGE, Mass., March 2, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer will present a corporate overview at Raymond James Institutional Investors Conference, being held in Orlando on March 6-9, 2022.
Feb 11, 2022 07:30 am ET
Thinking about buying stock in Castor Maritime, Itau Unibanco, Bloom Energy, Cassava Sciences, or Leap Therapeutics?
NEW YORK, Feb. 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CTRM, ITUB, BE, SAVA, and LPTX.
Jan 31, 2022 06:00 am ET
Leica Biosystems and Leap Therapeutics Partner on Companion Diagnostic to Advance Care for Cancer Patients
CAMBRIDGE, Mass., Jan. 31, 2022 /PRNewswire/ -- Leica Biosystems, a cancer diagnostics company, has entered into an agreement with Leap Therapeutics (NASDAQ: LPTX), a biotechnology company, to develop a companion diagnostic to detect Dickkopf-related protein 1 (DKK1). The assay will be used to support clinical development of Leap Therapeutics' anti-DKK1 cancer therapy, DKN-01, currently being studied in clinical trials.
Jan 20, 2022 08:31 am ET
Thinking about buying stock in Baudax Bio, Standard Lithium, KE Holdings, EHang Holdings, or Leap Therapeutics?
NEW YORK, Jan. 20, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BXRX, SLI, BEKE, EH, and LPTX.
Jan 19, 2022 07:35 am ET
Thinking about buying stock in Zogenix, KE Holdings, SoFi Technologies, Leap Therapeutics, or ADMA Biologics?
NEW YORK, Jan. 19, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZGNX, BEKE, SOFI, LPTX, and ADMA.
Jan 18, 2022 04:00 pm ET
Leap Therapeutics to Present Positive New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ASCO GI Cancers Symposium
CAMBRIDGE, Mass., Jan. 18, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused  on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting updated data from the DisTinGuish study, a Phase 2a clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene's anti-PD-1 antibody, in patients with gastric or gastroesophageal junction cancer (G/GEJ), at the American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium being held on January
Jan 05, 2022 06:00 am ET
Leap Therapeutics to Present at H.C. Wainwright BioConnect 2022 Conference
CAMBRIDGE, Mass., Jan. 5, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright BioConnect 2022 Conference, being held virtually on January 10-13, 2022.
Jan 03, 2022 06:00 am ET
Leap Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 3, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference. The conference will be held in a virtual meeting format.
Nov 24, 2021 08:31 am ET
Thinking about buying stock in Ocuphire Pharma, Seelos Therapeutics, Anavex Life Sciences, Leap Therapeutics, or Oramed Pharmaceuticals?
NEW YORK, Nov. 24, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OCUP, SEEL, AVXL, LPTX, and ORMP.
Nov 15, 2021 06:00 am ET
Leap Therapeutics to Participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference
CAMBRIDGE, Mass., Nov. 15, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that members of the senior management team will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference, taking place on Monday, November 29 – Thursday, December 2, 2021.
Nov 12, 2021 06:00 am ET
Leap Therapeutics Reports Third Quarter 2021 Financial Results
CAMBRIDGE, Mass., Nov. 12, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2021.
Sep 29, 2021 09:31 am ET
Thinking about buying stock in NuCana, Gap, Li-Cycle, TG Therapeutics, or Leap Therapeutics?
NEW YORK, Sept. 29, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NCNA, GPS, LICY, TGTX, and LPTX.
Sep 24, 2021 12:00 pm ET
Leap Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
CAMBRIDGE, Mass., Sept. 24, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of a public offering of 27,568,072 shares of its common stock, which includes the sale of an additional 4,740,000 shares of its common stock pursuant to the full exercise of the underwriters' option to purchase additional shares, and of pre-funded warrants to purchase 8,771,928 shares of its common stock. The gross proceeds to Leap from this offering were approximately $104 million, includi
Sep 22, 2021 08:30 am ET
Leap Therapeutics Announces Pricing of $90 million of Common Stock and Pre-Funded Warrants
CAMBRIDGE, Mass., Sept. 22, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the pricing of an underwritten public offering of its common stock at a public offering price of $2.85 per share and of pre-funded warrants to purchase shares of its common stock at a public offering price of $2.849 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant. The gross proceeds to
Sep 21, 2021 04:01 pm ET
Leap Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
CAMBRIDGE, Mass., Sept. 21, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it has commenced an underwritten public offering of its common stock and, in lieu of common stock, Leap intends to offer and sell to certain investors pre-funded warrants to purchase shares of its common stock. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Leap. Leap intends to grant the underwriters a 30-day option to purchase up to an aggregate
Sep 16, 2021 08:30 am ET
Thinking about buying stock in The Metals Company, Leap Therapeutics, Phio Pharmaceuticals, Ion Geophysical, or Laureate Education?
NEW YORK, Sept. 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TMC, LPTX, PHIO, IO, and LAUR.
Sep 16, 2021 02:31 am ET
Leap Therapeutics Presents Updated Positive Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ESMO Congress
CAMBRIDGE, Mass., Sept. 16, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused  on developing targeted and immuno-oncology therapeutics, today announced the presentation of updated positive data from the first-line cohort of the DisTinGuish study, a Phase 2a clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene Ltd.'s anti-PD-1 antibody, and chemotherapy, in patients with gastric or gastroesophageal junction cancer (G/GEJ), at the European Society for Medical Oncology (ESMO) Congress. The C
Sep 13, 2021 08:30 am ET
Thinking about buying stock in Leap Therapeutics, Aterian, Hepion Pharmaceuticals, Adaptimmune Therapeutics, or Endo International?
NEW YORK, Sept. 13, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LPTX, ATER, HEPA, ADAP, and ENDP.
Sep 13, 2021 06:00 am ET
Leap Therapeutics to Present New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ESMO 2021 Congress
CAMBRIDGE, Mass., Sept. 13, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting initial data from the first-line cohort of the DisTinGuish study, a Phase 2a clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene Ltd.'s anti-PD-1 antibody, and chemotherapy, in patients with gastric or gastroesophageal junction cancer (G/GEJ), at the European Society for Medical Oncology (ESMO) Congress, bein
Sep 07, 2021 07:00 am ET
Leap Therapeutics to Participate at Two Upcoming Virtual Investor Conferences
CAMBRIDGE, Mass., Sept. 7, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will participate in two upcoming virtual investor conferences:
Aug 13, 2021 07:00 am ET
Leap Therapeutics Reports Second Quarter 2021 Financial Results and Upcoming Data Presentation
CAMBRIDGE, Mass., Aug. 13, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter ended June 30, 2021 and provided upcoming company milestones.
Jul 26, 2021 07:00 am ET
Leap Therapeutics to Present at the ESMO 2021 Virtual Congress
CAMBRIDGE, Mass., July 26, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting initial data from the DisTinGuish study, a Phase 2a clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene's Ltd.'s anti-PD-1 antibody, with or without chemotherapy, in patients with gastric or gastroesophageal junction cancer (G/GEJ), at the European Society for Medical Oncology (ESMO) Congress, being held virtu
Jul 07, 2021 07:00 am ET
Leap Therapeutics to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference
CAMBRIDGE, Mass., July 7, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on Wednesday, July 14, 2021 at 1:00 p.m. Eastern Time.
Jun 14, 2021 07:00 am ET
Leap Therapeutics to Present at Raymond James 2021 Virtual Human Health Innovation Conference
CAMBRIDGE, Mass., June 14, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at the Raymond James 2021 Virtual Human Health Innovation Conference on Monday, June 21, 2021 at 1:20 p.m. Eastern Time.
Feb 22, 2021 06:00 am ET
Leap Therapeutics to Present at Upcoming Virtual Investor Conferences
CAMBRIDGE, Mass., Feb. 22, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at the following virtual investor conferences:
Jan 06, 2021 06:00 am ET
Leap Therapeutics to Present at H.C. Wainwright BioConnect 2021 Conference
CAMBRIDGE, Mass., Jan. 6, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright BioConnect 2021 Conference, being held virtually on January 11-14, 2021.
Jan 04, 2021 06:00 am ET
Leap Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 4, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference. The conference will be held in a virtual meeting format.
Dec 22, 2020 09:17 am ET
Leap Therapeutics Announces Publication of DKN-01 Mechanism of Action Data in Molecular Cancer Research
CAMBRIDGE, Mass., Dec. 22, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the publication in Molecular Cancer Research of preclinical results from studies of human and murine versions of DKN-01, a humanized monoclonal antibody that binds to and blocks the activity of the Dickkopf-1 (DKK1) protein. The article, entitled "mDKN-01, a Novel Anti-DKK1 Monoclonal Antibody, Enhances Innate Immune Responses in the Tumor Microenvironment," is available online. The studies characterize
Nov 23, 2020 06:00 am ET
Leap Therapeutics to Participate at Piper Sandler 32nd Annual Virtual Healthcare Conference
CAMBRIDGE, Mass., Nov. 23, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held on December 1-3, 2020.
Nov 12, 2020 06:00 am ET
Leap Therapeutics Reports Third Quarter 2020 Financial Results
CAMBRIDGE, Mass., Nov. 12, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2020.
Nov 10, 2020 06:00 am ET
Leap Therapeutics to Present at Stifel 2020 Healthcare Conference
CAMBRIDGE, Mass., Nov. 10, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at the Stifel 2020 Virtual Healthcare Conference, being held on November 16-18, 2020.
Nov 09, 2020 08:30 am ET
Leap Therapeutics Presents DKN-01 Monotherapy Data at AACR Virtual Special Endometrial Cancer Conference
CAMBRIDGE, Mass., Nov. 9, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the presentation of clinical data from its Phase 2 clinical trial of DKN-01 in patients with recurrent epithelial endometrial cancers (EEC) at the AACR Virtual Special Conference on Endometrial Cancer: New Biology Driving Research and Treatment being held November 9-10, 2020. DKN-01 is a humanized monoclonal antibody that binds to and blocks the activity of the Dickkopf-1 (DKK1) protein.
Nov 09, 2020 07:00 am ET
Leap Therapeutics Presents Updated Data for DKN-01 in Esophagogastric Cancer Patients at SITC 2020 35th Annual Meeting
CAMBRIDGE, Mass., Nov. 9, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the presentation of clinical data from its Phase 1b/2a clinical trial of DKN-01 in patients with advanced esophagogastric cancer (EGC) at the Society for Immunotherapy of Cancer's 35th Anniversary Annual Meeting. DKN-01 is a humanized monoclonal antibody that binds to and blocks the activity of the Dickkopf-1 (DKK1) protein.
Oct 15, 2020 07:00 am ET
Leap Therapeutics to Present Esophagogastric Cancer Data at SITC 2020 Annual Meeting
CAMBRIDGE, Mass., Oct. 15, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting esophagogastric cancer data for its DKN-01 monoclonal antibody at the Society of Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting, being held November 9-14, 2020 virtually.
Jun 25, 2020 04:05 pm ET
Leap Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
CAMBRIDGE, Mass., June 25, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of an additional 3,375,000 shares of common stock pursuant to the full exercise of the underwriters' option to purchase additional shares from Leap's previously announced public offering. After giving effect to the full exercise of the option, the aggregate gross proceeds to Leap from this offering were approximately $51.75 million, before deducting underwriting discounts and commissi
Jun 22, 2020 04:05 pm ET
Leap Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants
CAMBRIDGE, Mass., June 22, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of a public offering of 20,250,000 shares of common stock and pre-funded warrants to purchase up to 2,250,000 shares of its common stock. The gross proceeds to Leap from this offering were approximately $45 million, before deducting underwriting discounts and commissions and other offering expenses payable by Leap.
Jun 18, 2020 09:00 am ET
Leap Therapeutics Announces Pricing of $45 Million of Common Stock and Pre-Funded Warrants
CAMBRIDGE, Mass., June 18, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the pricing of an underwritten public offering of its common stock at a public offering price of $2.00 per share and of pre-funded warrants to purchase shares of its common stock at a public offering price of $1.999 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant. The gross proceeds to
Jun 17, 2020 04:01 pm ET
Leap Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
CAMBRIDGE, Mass., June 17, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it has commenced an underwritten public offering of its common stock and, in lieu of common stock, Leap intends to offer and sell to certain investors pre-funded warrants to purchase shares of its common stock. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Leap. Leap intends to grant the underwriters a 30-day option to purchase up to an aggregate o
Jun 11, 2020 04:06 pm ET
Leap Therapeutics Announces Oprhan Drug Designation of DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer
CAMBRIDGE, Mass., June 11, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation for DKN-01 for the treatment of gastric and gastroesophageal junction cancer. DKN-01 is a humanized monoclonal antibody that binds to and blocks the activity of the Dickkopf-1 (DKK1) protein, a modulator of Wnt/Beta-catenin signaling.
Jun 11, 2020 04:05 pm ET
Leap Therapeutics Announces Changes to Virtual Format and Time for 2020 Annual Meeting of Stockholders
CAMBRIDGE, Mass., June 11, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that, due to public health and safety concerns related to the outbreak of the novel coronavirus ("COVID-19"), and to support the health and well-being of its stockholders, employees and others, the Company is changing its 2020 Annual Meeting of Stockholders (the "Annual Meeting") to a virtual-only format. The virtual Annual Meeting is expected to provide stockholders with the same rights and opportunit
May 14, 2020 07:00 am ET
Leap Therapeutics Reports First Quarter 2020 Financial Results
CAMBRIDGE, Mass., May 14, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2020.
Apr 23, 2020 07:00 am ET
Leap Therapeutics to Present Updated Data for DKN-01 Monotherapy and Paclitaxel Combination In Gynecologic Cancers
CAMBRIDGE, Mass., April 23, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced updated clinical data from its ongoing Phase 2 clinical trial of DKN-01, its anti-Dickkopf-1 (DKK1) antibody, as both a monotherapy and in combination with paclitaxel chemotherapy in patients with advanced gynecological malignancies. Leap will host a conference call with Rebecca Arend, M.D., Assistant Professor and Associate Scientist, Gynecologic Oncology Clinic, The University of Alabama at Birmingh
Mar 18, 2020 07:00 am ET
Leap Therapeutics Announces Executive Leadership Changes
CAMBRIDGE, Mass., March 18, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced changes to the Company's Executive Leadership Team. All changes to the Board of Directors are effective immediately. Other management changes will take effect April 1, 2020, and include the following:
Mar 16, 2020 07:00 am ET
Leap Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
CAMBRIDGE, Mass., March 16, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2019.
Nov 14, 2019 06:00 am ET
Leap Therapeutics Reports Third Quarter 2019 Financial Results
CAMBRIDGE, Mass., Nov. 14, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX) today reported financial results for the third quarter ended September 30, 2019.
Sep 17, 2019 07:00 am ET
Leap Therapeutics to Present Updated Data for DKN-01 Monotherapy and Paclitaxel Combination at the 2019 International Gynecologic Cancer Society Annual Global Meeting
CAMBRIDGE, Mass., Sept. 17, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX) today announced an oral and poster presentation of updated clinical data from its ongoing Phase 2 clinical trial of DKN-01, its anti-Dickkopf-1 (DKK1) antibody, as both a monotherapy and in combination with paclitaxel chemotherapy in patients with advanced gynecological malignancies will be presented at the 2019 International Gynecologic Cancer Society Annual Global Meeting taking place September 19-21, 2019 in Rio de Janeiro, Brazil. The poster will be presented on Friday, September 20 at 6:15 p.m. (BRT)
Sep 04, 2019 07:00 am ET
Leap Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Sept. 4, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that Christopher K. Mirabelli, Ph.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the following investor conferences:
Aug 09, 2019 07:00 am ET
Leap Therapeutics Reports Second Quarter 2019 Financial Results
CAMBRIDGE, Mass., Aug. 9, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter ended June 30, 2019.
Aug 06, 2019 07:00 am ET
Leap Presents Positive Clinical Results for the Combination of DKN-01 plus Keytruda® and Provides DKN-01 Program Update
CAMBRIDGE, Mass., Aug. 6, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX) today announced that its anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with Merck's anti-PD-1 antibody, Keytruda® (pembrolizumab), demonstrated higher survival and objective response outcomes in patients with advanced gastroesophageal junction and gastric cancer (GEJ/GC) whose tumors expressed high levels of DKK1 (DKK1-high).  DKN-01 plus Keytruda therapy achieved over 22 weeks median progression-free survival (PFS) and nearly 32 weeks median overall survival (OS) with a 50% overall response rate
Jul 25, 2019 07:00 am ET
Leap Therapeutics to Host Conference Call to Provide DKN-01 Program Update
CAMBRIDGE, Mass., July 25, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it will host a conference call on August 6, 2019, to provide a program update for DKN-01, a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers.
Jul 11, 2019 08:00 am ET
Leap Therapeutics Announces Common Stock Purchase Agreements For Up to $21 Million with Lincoln Park Capital
CAMBRIDGE, Mass., July 11, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced it has entered into common stock purchase agreements for up to $21 million with Lincoln Park Capital Fund, LLC ("LPC"), a Chicago-based institutional investor and current shareholder.
May 15, 2019 07:00 am ET
Leap Therapeutics Reports First Quarter 2019 Financial Results
CAMBRIDGE, Mass., May 15, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2019.
Apr 12, 2019 08:00 am ET
Factors of Influence in 2019, Key Indicators and Opportunity within IDEXX Laboratories, Aegion, NetScout, Castlight Health, inc, Leap Therapeutics, and Speedway Motorsports — New Research Emphasizes E
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of IDEXX Laboratories, Inc. (NASDAQ:IDXX), Aegion Corporation...
Apr 03, 2019 07:00 am ET
Leap Therapeutics to Present at the 2019 Needham & Company 18th Annual Healthcare Conference
CAMBRIDGE, Mass., April 3, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Christopher K. Mirabelli, Ph.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the 2019 Needham & Company 18th Annual Healthcare Conference, being held in New York City on April 9-10, 2019.
Apr 01, 2019 04:05 pm ET
Leap Therapeutics Reports Clinical Update and 2018 Financial Results
CAMBRIDGE, Mass., April 1, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported an update on its clinical development programs along with financial results for the fourth quarter and year ended December 31, 2018.
Mar 18, 2019 07:00 am ET
Leap Therapeutics Presents at Society of Gynecologic Oncology 50th Annual Meeting on Women's Cancer
CAMBRIDGE, Mass., March 18, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX) today announced the presentation of clinical data from its ongoing Phase 2 clinical trial of DKN-01 in patients with advanced gynecological malignancies at the Society of Gynecologic Oncology 50th Annual Meeting on Women's Cancer. Patients, including those with carcinosarcoma and Wnt pathway alterations, have experienced partial responses and durable clinical benefit in both the monotherapy and combination arms of the study. The complete data set will become available in the coming months as the most recen
Mar 08, 2019 06:00 am ET
Leap Therapeutics to Present at the Society of Gynecologic Oncology 2019 Annual Meeting on Women's Cancer
CAMBRIDGE, Mass., March 8, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting at the Society of Gynecologic Oncology 2019 Annual Meeting on Women's Cancer, being held March 16-19, 2019 in Honolulu, HI.
Feb 05, 2019 12:29 pm ET
Leap Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Securities
CAMBRIDGE, Mass., Feb. 5, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of an underwritten public offering of 6,571,428 shares of its common stock and warrants to purchase up to 6,571,428 shares of its common stock, as well as an additional 985,714 shares of its common stock and warrants to purchase up to 985,714 shares of its common stock pursuant to the full exercise of the underwriters' option to purchase additional securities. Total gross proceeds to Leap
Feb 01, 2019 08:28 am ET
Leap Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock and Warrants
CAMBRIDGE, Mass., Feb. 1, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the pricing of an underwritten public offering of 6,571,428 shares of its common stock and warrants to purchase up to 6,571,428 shares of its common stock. Each share of common stock is being sold together with a warrant to purchase one share of common stock for a combined offering price of $1.75 per share and accompanying warrant. The warrants will be exercisable commencing on the date of issuance, wil
Jan 29, 2019 08:10 am ET
Report: Developing Opportunities within Match Group, Antero Resources, Boyd Gaming, Gorman-Rupp, Leap Therapeutics, and BioPharmX — Future Expectations, Projections Moving into 2019
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Match Group, Inc. (NASDAQ:MTCH), Antero Resources Corporation...
Jan 14, 2019 06:00 am ET
Leap Therapeutics Announces an Investigator-Initiated Study of DKN-01 in Patients with DKK1+ Advanced Prostate Cancer
CAMBRIDGE, Mass., Jan. 14, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced an investigator-initiated study led by David R. Wise, M.D., Ph.D. of the Perlmutter Cancer Center at NYU Langone Health to study DKN-01, as a monotherapy and in combination with docetaxel in patients with advanced prostate cancer. This clinical trial is specifically targeting a biomarker-selected patient population in metastatic castration-resistant prostate cancer (mCRPC) with elevated Dickkopf-1 (DKK1) levels.
Dec 14, 2018 06:00 am ET
Leap Therapeutics Presents TRX518 Data at ESMO Immuno-Oncology Congress 2018 and Updated Data from DKN-01 Study in Biliary Tract Cancer
CAMBRIDGE, Mass., Dec. 14, 2018 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX) today presented clinical data from its ongoing Phase I/II study of TRX518 in combination with gemcitabine, KeytrudaÒ (pembrolizumab), or OpdivoÒ (nivolumab) in patients with advanced solid tumors at the European Society for Molecular Oncology (ESMO) Immuno-Oncology Congress 2018.  In addition, Leap provided the top-line final data from the Phase I/II study of DKN-01 in combination with gemcitabine and cisplatin chemotherapy in patients with advanced biliary tract cancer.
Nov 09, 2018 06:05 am ET
Leap Therapeutics Reports Third Quarter 2018 Business Update and Financial Results
CAMBRIDGE, Mass., Nov. 9, 2018 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported a business update and financial results for the third quarter ended September 30, 2018.
Nov 09, 2018 06:00 am ET
Leap Therapeutics Presents Esophagogastric Cancer Data at SITC 2018 Annual Meeting
CAMBRIDGE, Mass., Nov. 9, 2018 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX) today presented clinical data from its ongoing Phase I/II study of DKN-01 in combination with paclitaxel in patients with advanced esophagogastric cancer at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting (SITC 2018).
Oct 21, 2018 06:45 am ET
Leap Therapeutics Presents Esophagogastric Cancer Data at ESMO 2018 Annual Congress
CAMBRIDGE, Mass., Oct. 21, 2018 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX) today presented clinical data from its ongoing Phase I/II study of DKN-01 in combination with Keytruda® (pembrolizumab) in patients with advanced esophagogastric cancer at the European Society for Molecular Oncology (ESMO) 2018 Annual Congress.
Oct 17, 2018 09:00 am ET
Market Trends Toward New Normal in Halozyme Therapeutics, Fitbit, Iconix Brand Group, Leap Therapeutics, LightPath Technologies, and Capricor Therapeutics — Emerging Consolidated Expectations, Analyst
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Halozyme Therapeutics, Inc. (NASDAQ:HALO), Fitbit, Inc. (NYSE:FIT),...
Oct 08, 2018 06:35 pm ET
Leap Therapeutics to Present Data from Study Evaluating DKN-01 in Combination with KEYTRUDA® (pembrolizumab) at the European Society of Medical Oncology 2018 Congress
CAMBRIDGE, Mass., Oct. 8, 2018 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that data from the study of DKN-01 in combination with KEYTRUDA® (pembrolizumab) in patients with advanced gastroesophageal cancer will be presented in a poster presentation at the European Society of Medical Oncology (ESMO) 2018 Annual Congress, taking  place October 19-23, 2018 in Munich, Germany. The abstract was published online in advance of the poster presentation that will include additional patient data as
Sep 25, 2018 07:00 am ET
Leap Therapeutics to Present at Two October Conferences
CAMBRIDGE, Mass., Sept. 25, 2018 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that Christopher K. Mirabelli, Ph.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the following investor conferences:
Aug 30, 2018 04:05 pm ET
Leap Therapeutics to Participate in the H.C. Wainwright 20th Annual Global Investment Conference
CAMBRIDGE, Mass., Aug. 30, 2018 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that Christopher K. Mirabelli, Ph.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 20th Annual Global Investment Conference, being held in New York City on September 4-6, 2018.
Aug 22, 2018 07:40 am ET
Recent Analysis Shows Leap Therapeutics, Gardner Denver, Medical Transcription Billing, CarGurus, Liberty Media, and Quorum Health Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Leap Therapeutics, Inc. (NASDAQ:LPTX), Gardner Denver Holdings, Inc....
Aug 08, 2018 07:00 am ET
Leap Therapeutics Reports Second Quarter 2018 Business Update and Financial Results
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported a business update and financial results for the second quarter ended June 30, 2018. “Over the past few months, we...
Jul 23, 2018 07:30 am ET
Leap Therapeutics Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Combination of TRX518, Avelumab, and Chemotherapy in Advanced Solid Tumors
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced it has entered into a collaboration agreement with Merck KGaA, Darmstadt, Germany, and Pfizer to evaluate Leap’s...
Jun 13, 2018 07:55 am ET
Analysis: Positioning to Benefit within Ruth's Hospitality Group, S&P Global, Shaw Communications, Leap Therapeutics, Red Hat, and Welltower — Research Highlights Growth, Revenue, and Consolidated Res
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ruth's Hospitality Group, Inc. (NASDAQ:RUTH), S Global Inc. (NYSE:SPGI),...
Jun 13, 2018 07:00 am ET
Leap Therapeutics to Present at the 2018 JMP Securities Life Sciences Conference
Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that Christopher K. Mirabelli, Ph.D., Chairman, President and Chief Executive Officer, will present a corporate...
May 11, 2018 07:00 am ET
Leap Therapeutics Reports First Quarter 2018 Financial Results
Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2018. “We had a strong first quarter, as we presented data...
Apr 16, 2018 09:00 am ET
Leap Therapeutics Presents Nonclinical and Clinical Data on DKN-01 at AACR 2018 Annual Meeting
CAMBRIDGE, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX) today presented nonclinical and clinical data on DKN-01, Leap’s anti-DKK1 monoclonal antibody, at the American Association for Cancer Research (AACR) 2018 Annual Meeting. The presentation highlighted...
Mar 28, 2018 08:00 am ET
New Research Coverage Highlights Holly Energy Partners, Liberty Property Trust, Fair Isaac, 58, Cousins Properties, and Leap Therapeutics — Consolidated Revenues, Company Growth, and Expectations for
NEW YORK, March 28, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Holly Energy Partners, L.P. (NYSE:HEP), Liberty...
Mar 27, 2018 04:05 pm ET
Leap Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
CAMBRIDGE, Mass., March 27, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of a public offering of 2,146,667 shares of its common stock, which...
Mar 23, 2018 09:00 am ET
Leap Therapeutics Announces Pricing of $14 Million Public Offering of Common Stock
CAMBRIDGE, Mass., March 23, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the pricing of an underwritten public offering of 1,866,667 shares of its common stock...
Mar 22, 2018 04:05 pm ET
Leap Therapeutics Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., March 22, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it has commenced an underwritten public offering of its common stock. All shares...
Mar 21, 2018 07:00 am ET
Leap Therapeutics to Present at the 2018 Needham & Company 17th Annual Healthcare Conference
CAMBRIDGE, Mass., March 21, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that Christopher K. Mirabelli, Ph.D, Chairman, President, and Chief Executive Officer, will present a corporate overview...
Mar 14, 2018 05:00 pm ET
Leap Therapeutics Provides DKN-01 Program Update and Announces Scientific Presentations at AACR Annual Meeting
CAMBRIDGE, Mass., March 14, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today presented promising clinical data from the study evaluating DKN-01, Leap’s anti-DKK1 monoclonal antibody, as a monotherapy in...
Mar 07, 2018 07:00 am ET
Leap Therapeutics to Present at 2018 Barclays Global Healthcare Conference
CAMBRIDGE, Mass., March 07, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that Christopher K. Mirabelli, Ph.D, Chairman, President, and Chief Executive Officer, will present a corporate overview...
Feb 23, 2018 07:00 am ET
Leap Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Announces Date of its Annual Meeting of Stockholders
CAMBRIDGE, Mass., Feb. 23, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2017. Leap additionally announced that...
Feb 06, 2018 07:00 am ET
Leap Therapeutics to Present at the 20th Annual BIO CEO & Investor Conference
CAMBRIDGE, Mass., Feb. 06, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, Chief Financial Officer, will present a corporate overview at the 20th Annual...
Jan 16, 2018 07:00 am ET
Leap Therapeutics Announces First Patient Dosed with TRX518 Combination Therapy in Advanced Solid Tumors Trial
CAMBRIDGE, Mass., Jan. 16, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that the first patient has been dosed in a Phase 1 clinical trial evaluating Leap’s GITR...
Nov 15, 2017 07:00 am ET
Leap Therapeutics Announces $18 Million Private Placement Offering
CAMBRIDGE, Mass., Nov. 15, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced it has entered into a purchase agreement to issue and sell shares of its common stock...
Nov 13, 2017 07:00 am ET
Leap Therapeutics Reports Third Quarter 2017 Financial Results and Announces First Patient Dosed with DKN-01 and KEYTRUDA® (pembrolizumab) in Esophagogastric Cancer Trial
CAMBRIDGE, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2017. Leap additionally announced that the first...
Aug 11, 2017 07:00 am ET
Leap Therapeutics Reports Second Quarter 2017 Financial Results
CAMBRIDGE, Mass., Aug. 11, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter ended June 30, 2017....
May 17, 2017 05:16 pm ET
Leap Therapeutics Presents Positive DKN-01 Clinical Data in Biliary Tract Cancers at American Society of Clinical Oncology (ASCO) 2017 Annual Meeting
CAMBRIDGE, Mass., May 17, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported interim data from the Phase 1 study of DKN-01 in combination with standard of care chemotherapy in patients with advanced biliary tract cancers. Data from the study was published online as an abstract in advance of a poster presentation being held at the American Society of Clinical Oncology (ASCO) Annual Meeting held June 2 - 6, 2017 in Chicago, Illinois.  ...
Mar 31, 2017 04:36 pm ET
Leap Therapeutics Reports Full Year 2016 Financial Results and Progression-Free Survival Data in Advanced Biliary Tract Cancers
CAMBRIDGE, Mass., March 31, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported financial results for the year ended December 31, 2016 and top-line progression-free survival (PFS) data....
Mar 01, 2017 06:39 pm ET
Leap Therapeutics to Present Preclinical and Clinical Data at 2017 AACR Annual Meeting
CAMBRIDGE, Mass., March 01, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced preclinical and clinical data presentations will be made during the 2017 American Association for Cancer Research (AACR) Annual Meeting, being held April 1 - 5, 2017, in Washington, D.C. Data on TRX518 will be presented as an oral presentation in a clinical trials plenary session by Roberta Zappasodi, Ph.D., Parker Institute Scholar and Research Scholar in the Ludwig Collaborative Laboratory at Memorial Slo...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.